Feasibility and Implication of Routine NGS Analysis in Neuroendocrine Carcinomas
Introduction: Neuroendocrine carcinomas (NECs) may arise from any organ system, exhibit various degree of differentiation and have Ki67 indices ranging from 21-100%. After first-line platin based chemotherapy, no standard treatment exists.
Aim(s): In order to further characterize NECs as well as to screen for potential eligibility for second line targeted treatment, we prospectively conducted next generation sequencing (NGS) analysis in patients with NEC.
Materials and methods: Patients with NEC who were referred to the Copenhagen NET Center between Oct. 2015 and Oct. 2016, and having in-house pathological specimens available, were entered prospectively. Extracted genomic DNA was analyzed using the AmpliSeq Cancer Hotspot Lung-Colon Panel version 2 covering the most frequent hot spot mutations in 50 selected genes.
Conference: 14th Annual ENETSConcerence (2017)
To read the full abstract, please log into your ENETS Member account.